December 22, 2014
72,682
1,031
569
2.20%
Every word spoken in this episode is indexed. Type any phrase to jump straight to the moment it was said.
Type any word or phrase that may have been spoken. Click a result to seek the player to that exact moment.
Try a name, a topic, or a quoted line
See what was published immediately before and after this episode.
6:55Now Playing"Some argue that a female sexual-dysfunction drug is a matter of equality among the sexes. Others say it creates a medical problem where none exists.
“Aren’t women’s sexual needs as important as erectile dysfunction in men?” To hear one side tell it, that’s the central issue in the debate over what’s known as “pink Viagra,” a sexual-dysfunction drug for women. Health organizations and the pharmaceutical industry say the absence of a female drug is a pressing problem that affects millions of relationships in the U.S. every year—and is the result of decades of inequality in scientific research. On the other hand, some researchers believe these groups, along with the drug industry, are creating a medical need where one doesn’t really exist, and that there isn’t a double standard at play in rejecting the latest female drug, flibanserin. As they see it, pink pill advocates are co-opting the language of equality, while drug marketers ignore the complexities of female sexual dysfunction, and how best to treat it."
Read more here
Cenk Uygur () and Ana Kasparian () of The Young Turks discuss. Tell us what you think in the comment section below.
Support TYT for FREE by doing your Amazon shopping through this link (bookmark it!)
Sentinel Indexing in Progress
Metadata and chapters are available. Claim extraction for this episode is pending.
All video content is delivered via YouTube embedded players in accordance with the YouTube Terms of Service. Sentinel provides research tools that promote discovery and accountability across political media.